nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.02.2014 | Therapy in Practice

Acne in Patients with Skin of Color: Practical Management

verfasst von: Natalie C. Yin, Amy J. McMichael

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Acne vulgaris is a prevalent and non-discriminatory condition affecting individuals of all races and ethnicities. As people with skin of color make up a rapidly expanding segment of the US population, dermatologic care must evolve accordingly to address their distinct concerns. Patients with skin of color with acne can be particularly challenging, given their potential for cosmetically disturbing complications, including post-inflammatory hyperpigmentation and keloid development. A variety of treatments have been shown to be effective in preventing or treating these complications. Topical retinoids are considered first-line therapy for acne in patients of color; topical alternatives include azelaic acid, dapsone, and antimicrobials. Hydroquinone may be used in combating post-inflammatory hyperpigmentation, specifically. For more severe acne, oral agents, including oral antibiotics or isotretinoin, may be used. Most recently, various lasers and phototherapies have been suggested for their safety and efficacy in patients with skin of color with acne. Ultimately, recognizing the clinical and histologic differences, as well as the variations in treatment regimens for darker skin types will allow for better care and patient satisfaction.

Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–72. doi:10.1016/S0140-6736(11)60321-8.PubMedCrossRef

White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39(2 Pt 3):S34–7.PubMedCrossRef

Bureau UC. US Census Bureau news: more diversity, slower growth; 2004. http://www.census.gov/Press-Release/www/releases/archives/population/001720.html (Accessed 6 June 2013).

Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatol Treat. 2010;21(3):206–11. doi:10.3109/09546630903401496.CrossRef

Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21(4):609–15, vii.

Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol. 1983;1(2):157–64.PubMedCrossRef

Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512–7.PubMedCrossRef

Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.PubMed

Halder RM, Grimes PE, McLaurin CI, et al.. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388–390.

10.

Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21(4):601–7.PubMedCrossRef

11.

Arsouze A, Fitoussi C, Cabotin PP, Chaine B, Delebecque C, Raynaud E, et al. Presenting skin disorders in black Afro-Caribbean patients: a multicentre study conducted in the Paris region. Annales de dermatologie et de venereologie. 2008;135(3):177–82. doi:10.1016/j.annder.2007.11.008.PubMedCrossRef

12.

Dunwell P, Rose A. Study of the skin disease spectrum occurring in an Afro-Caribbean population. Int J Dermatol. 2003;42(4):287–9.PubMedCrossRef

13.

Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11(4):466–73.PubMed

14.

Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25(9):1054–60. doi:10.1111/j.1468-3083.2010.03919.x.PubMedCrossRef

15.

Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24–38.PubMedCentralPubMed

16.

Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.PubMedCentralPubMed

17.

Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17(2):184–95. doi:10.1111/j.1396-0296.2004.04019.x.PubMedCrossRef

18.

Grimes PE, Stockton T. Pigmentary disorders in blacks. Dermatol Clin. 1988;6(2):271–81.PubMed

19.

Coley MK, Alexis AF. Managing common dermatoses in skin of color. Semin Cutan Med Surg. 2009;28(2):63–70. doi:10.1016/j.sder.2009.04.006.PubMedCrossRef

20.

Halder RM, Holmes YC, Bridgeman-Shah S, Klingman AM. A clinicohistopathological study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.

21.

Halder RM, Roberts CI, Nootheti PK. Cutaneous diseases in the black races. Dermatol Clin. 2003;21(4):679–87, ix.

22.

Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S98–106.

23.

Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;43(5):362–5. doi:10.1111/j.1365-4632.2004.02267.x.PubMedCrossRef

24.

Kelly AP. Update on the management of keloids. Semin Cutan Med Surg. 2009;28(2):71–6. doi:10.1016/j.sder.2009.04.002.PubMedCrossRef

25.

Kelly AP. Keloids: pathogenesis and treatment. Cosmetic Dermatol. 2003;16:29–32.

26.

Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol. 2001;137(11):1429–34.PubMedCrossRef

27.

Cole PD, Hatef DA, Taylor S, Bullocks JM. Skin care in ethnic populations. Semin Plastic Surg. 2009;23(3):168–72. doi:10.1055/s-0029-1224795.CrossRef

28.

Wilkins JW Jr, Voorhees JJ. Prevalence of nodulocystic acne in white and Negro males. Arch Dermatol. 1970;102(6):631–4.PubMedCrossRef

29.

Lee CS, Lim HW. Cutaneous diseases in Asians. Dermatol Clin. 2003;21(4):669–77.PubMedCrossRef

30.

Luther N, Darvin ME, Sterry W, Lademann J, Patzelt A. Ethnic differences in skin physiology, hair follicle morphology and follicular penetration. Skin Pharmacol Physiol. 2012;25(4):182–91. doi:10.1159/000337933.PubMedCrossRef

31.

Nicolaides N, Rothman S. Studies on the chemical composition of human hair fat: II. The overall composition with regard to age, sex and race. J Invest Dermatol. 1953;21(1):9–14.PubMed

32.

Kligman AM, Shelley WB. An investigation of the biology of the human sebaceous gland. J Invest Dermatol. 1958;30(3):99–125.PubMed

33.

Pochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin. 1988;6(3):349–51.PubMed

34.

Grimes P, Edison BL, Green BA, Wildnauer RH. Evaluation of inherent differences between African American and white skin surface properties using subjective and objective measures. Cutis. 2004;73(6):392–6.PubMed

35.

Roh M, Han M, Kim D, Chung K. Sebum output as a factor contributing to the size of facial pores. Br J Dermatol. 2006;155(5):890–4. doi:10.1111/j.1365-2133.2006.07465.x.PubMedCrossRef

36.

Rawlings AV. Ethnic skin types: are there differences in skin structure and function? Int J Cosmet Sci. 2006;28(2):79–93. doi:10.1111/j.1467-2494.2006.00302.x.PubMedCrossRef

37.

Kuenali S. Retinoids. Dermatology. 2nd ed. Elsevier Mosby; 2009.

38.

Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43. doi:10.1056/NEJM199305203282002.PubMedCrossRef

39.

Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45–50.PubMed

40.

Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048–65. doi:10.1016/j.jaad.2006.02.009.PubMedCrossRef

41.

Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):S98–103.PubMedCrossRef

42.

Jacyk WK, Mpofu P. Adapalene gel 0.1 % for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(4 Suppl):48–54.

43.

Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. Cutis. 2002;70(4):243–8.PubMed

44.

Zhu XJ, Tu P, Zhen J, et al. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis. 2001;68(4 Suppl):55–9.

45.

Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci. 2008;49(3):241–8. doi:10.1016/j.jdermsci.2007.09.012.PubMedCrossRef

46.

Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71(2 Suppl):18–26.PubMed

47.

Shavin J, Weiss J. Implications of the BEST study. Cutis. 2003;71(2 Suppl):35–6.PubMed

48.

Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1 Suppl):15–20.PubMed

49.

Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol. 2010;3(8):15–9.PubMedCentralPubMed

50.

Eichenfield LF, Krakowski AC. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. J Drugs Dermatol. 2012;11(7):818–24.PubMed

51.

Cook-Bolden FE. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2012;11(4):455–9.PubMed

52.

Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11(5):643–8.PubMed

53.

Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–15.PubMed

54.

Callender VD, Young CM, Kindred C, et al. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25–32.

55.

Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439 e1–10. doi:10.1016/j.jaad.2006.10.005.

56.

Fleischer AB Jr, Shalita A, Eichenfield LF, Abramovits W, Lucky A, Garrett S, et al. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol. 2010;9(1):33–40.PubMed

57.

Research CfDEa. Application number 21-794, Aczone (dapsone) gel 5%. Microbiology Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021794s000_MicroR (Accessed 8 June 2013).

58.

Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144(12):1564–70. doi:10.1001/archdermatol.2008.518.PubMedCrossRef

59.

Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol. 2010;9(5):532–6.PubMed

60.

Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6(10):981–7.PubMed

61.

Aczone (dapsone) gel 5 % [package insert]. Irvine: Allergan Inc.; 2009.

62.

Webster G. Combination azelaic acid therapy for acne vulgaris. J Am Acad Dermatol. 2000;43(2 Pt 3):S47–50.PubMedCrossRef

63.

Gollnick HP, Graupe K, Zaumseil RP. Azelaic acid 15% gel in the treatment of acne vulgaris: combined results of two double-blind clinical comparative studies. J German Soc Dermatol. 2004;2(10):841–7.

64.

Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41(5):780–98.PubMedCrossRef

65.

Hsu S, Quan LT. Topical antibacterial agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy; 2001. p. 473–496.

66.

Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586–90.PubMed

67.

Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59.PubMedCrossRef

68.

Bolognia J, Jorizzo JL, Rapini RP. Dermatology. New York: Mosby; 2003.

69.

Chandra M, Levitt J, Pensabene CA. Hydroquinone therapy for post-inflammatory hyperpigmentation secondary to acne: not just prescribable by dermatologists. Acta Derm Venereol. 2012;92(3):232–5. doi:10.2340/00015555-1225.PubMedCrossRef

70.

Glenn M, Grimes PE, Pitt E, Chalet M, Kelly AP. Evaluation of clinical and light microscopic effects of various concentrations of hydroquinone [abstract]. Clin Res. 1991;39:83A.

71.

Costa A, Moises TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. Anais brasileiros de dermatologia. 2010;85(5):613–20.PubMedCrossRef

72.

Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308–13. doi:10.1111/j.1529-8019.2007.00144.x.PubMedCrossRef

73.

Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin. J Natl Med Assoc. 1987;79(12):1266–70.PubMed

74.

Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10(3):153–68. doi:10.2165/00128071-200910030-00002.PubMedCrossRef

75.

Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–32. doi:10.1111/j.1600-0625.2009.00890.x.PubMedCrossRef

76.

Goulden V. Guidelines for the management of acne vulgaris in adolescents. Pediatr Drugs. 2003;5(5):301–13.

77.

Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–37. doi:10.1067/mjd.2003.618.PubMedCrossRef

78.

Tanghetti E. The impact and importance of resistance. Cutis. 2007;80(1 Suppl):5–9.PubMed

79.

Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 2003;206(1):54–6. doi:67822.PubMedCrossRef

80.

Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009;2(12):16–22.PubMedCentralPubMed

81.

Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009(2):CD000194. doi:10.1002/14651858.CD000194.pub2.

82.

Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498–502. doi:10.1067/mjd.2000.105557.PubMedCrossRef

83.

Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol. 2012;51(10):1162–74. doi:10.1111/j.1365-4632.2012.05519.x.PubMedCrossRef

84.

Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008;58(1):60–2. doi:10.1016/j.jaad.2007.09.024.PubMedCrossRef

85.

Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther. 2004;17(2):196–205. doi:10.1111/j.1396-0296.2004.04020.x.PubMedCrossRef

86.

Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients: a comparative study. Dermatol Surg. 1997;23(3):171–4 (discussion 5).

87.

Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25(1):18–22.PubMedCrossRef

88.

Godse K, Sakhia J. Triple combination and glycolic peels in post-acne hyperpigmentation. J Cutan Aesthet Surg. 2012;5(1):60–1. doi:10.4103/0974-2077.94335.PubMedCentralPubMedCrossRef

89.

Yeung CK, Shek SY, Yu CS, Kono T, Chan HH. Treatment of inflammatory facial acne with 1,450-nm diode laser in type IV to V Asian skin using an optimal combination of laser parameters. Dermatol Surg. 2009;35(4):593–600. doi:10.1111/j.1524-4725.2009.01097.x.PubMedCrossRef

90.

Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg. 2006;32(8):991–6 (discussion 6–7). doi:10.1111/j.1524-4725.2006.32221.x.

91.

Kim S, Cho KH. Treatment of facial postinflammatory hyperpigmentation with facial acne in Asian patients using a Q-switched neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2010;36(9):1374–80. doi:10.1111/j.1524-4725.2010.01643.x.PubMedCrossRef

92.

Chua SH, Ang P, Khoo LS, Goh CL. Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg. 2004;30(10):1287–91. doi:10.1111/j.1524-4725.2004.30402.x.PubMedCrossRef

93.

Alexis AF. Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV–VI. J Drugs Dermatol. 2011;10(12 Suppl):s6–7.PubMed

94.

Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12(4):428–31.PubMed

95.

Griffin AC. Laser resurfacing procedures in dark-skinned patients. Aesthet Surg J. 2005;25(6):625–7. doi:10.1016/j.asj.2005.09.019.PubMedCrossRef

96.

Badawi A, Tome MA, Atteya A, Sami N, Morsy IA. Retrospective analysis of non-ablative scar treatment in dark skin types using the sub-millisecond Nd:YAG 1,064 nm laser. Lasers Surg Med. 2011;43(2):130–6. doi:10.1002/lsm.21031.PubMedCrossRef

97.

Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vulgaris: the use of deep dermal heat in the treatment of moderate to severe active acne vulgaris (thermotherapy): a report of 22 patients. Dermatol Surg. 2003;29(4):333–9 (discussion 9).

98.

Elsaie ML, Choudhary S, Leiva A, Nouri K. Nonablative radiofrequency for skin rejuvenation. Dermatol Surg. 2010;36(5):577–89. doi:10.1111/j.1524-4725.2010.01510.x.PubMedCrossRef

99.

Lee SJ, Goo JW, Shin J, Chung WS, Kang JM, Kim YK, et al. Use of fractionated microneedle radiofrequency for the treatment of inflammatory acne vulgaris in 18 Korean patients. Dermatol Surg. 2012;38(3):400–5. doi:10.1111/j.1524-4725.2011.02267.x.PubMedCrossRef

100.

Terrell S, Aires D, Schweiger ES. Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patient. J Drugs Dermatol. 2009;8(7):669–71.PubMed

101.

Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nursing. 2004;16(5):401–6, 13–16 (quiz 17).

Titel: Acne in Patients with Skin of Color: Practical Management
verfasst von: Natalie C. Yin
Amy J. McMichael
Publikationsdatum: 01.02.2014
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2014
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-013-0049-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Treatment of Hereditary Epidermolysis Bullosa: Updates and Future Prospects

Oxidative Stress in Alopecia Areata: A Case–Control Study

Effect of Treating Psoriasis on Cardiovascular Co-Morbidities: Focus on TNF Inhibitors

Dermatitis Herpetiformis: Clinical Presentations Are Independent of Manifestations of Celiac Disease

Oral Therapy for Onychomycosis: An Evidence-Based Review